Understanding how certain proteins activate blood clotting and how to block this process
Roles of fibrin(ogen) in conformational activation of hemostatic proteinase precursors
['FUNDING_R01'] · VANDERBILT UNIVERSITY MEDICAL CENTER · NIH-11082522
This study is looking at how certain proteins in your blood help with clotting and how some bacteria can mess with that process, and it aims to create new treatments that could help prevent serious complications during infections, especially for those dealing with antibiotic-resistant bacteria.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY MEDICAL CENTER (nih funded) |
| Locations | 1 site (NASHVILLE, UNITED STATES) |
| Trial ID | NIH-11082522 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which prothrombin and plasminogen, proteins essential for blood clotting, are activated and how certain bacterial factors can hijack this process. The study focuses on developing monoclonal antibodies that can block the activity of these bacterial factors, potentially preventing complications such as thrombosis and bacterial spread during infections. By identifying specific sequences and binding sites involved in this activation, the research aims to provide new therapeutic strategies against antibiotic-resistant infections. Patients may benefit from advancements in treatments that target these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by antibiotic-resistant bacteria that may lead to complications like thrombosis.
Not a fit: Patients who do not have infections or those whose conditions are unrelated to blood clotting or antibiotic resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent dangerous blood clotting associated with bacterial infections, especially in the context of antibiotic resistance.
How similar studies have performed: Other research has shown promise in using monoclonal antibodies to target bacterial factors, indicating that this approach may be effective.
Where this research is happening
NASHVILLE, UNITED STATES
- VANDERBILT UNIVERSITY MEDICAL CENTER — NASHVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VERHAMME, INGRID M — VANDERBILT UNIVERSITY MEDICAL CENTER
- Study coordinator: VERHAMME, INGRID M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.